KYTX - Kyverna Therapeutics, Inc.

Insider Purchase by Westlake Biopartners Opportunity Fund I, L.P. (10%)

3 Months
After Trade
Before Trade

Loading data...

Trade Summary

2 months ago, Westlake Biopartners Opportunity Fund I, L.P., serving as 10% owner at Kyverna Therapeutics, Inc. (KYTX), purchased 133,333 shares at $7.50 per share, for a total transaction value of $999,998.00. Following this transaction, Westlake Biopartners Opportunity Fund I, L.P. now holds 4,657,257 shares of KYTX.

This purchase represents a 3.00% increase in Westlake Biopartners Opportunity Fund I, L.P.'s stake in the company. This is considered a medium-conviction trade.

The trade was executed on Thursday, December 18, 2025 and publicly disclosed via SEC Form 4 filing on Monday, December 22, 2025, 4 days after the trade was made.

Kyverna Therapeutics, Inc. operates in the HEALTHCARE sector, specifically within the BIOTECHNOLOGY industry. Insider buying activity in this sector can provide valuable signals about industry trends and company-specific developments.

Westlake Biopartners Opportunity Fund I, L.P.

10%

Westlake Biopartners Opportunity Fund I, L.P. is a venture capital fund managed by Westlake BioPartners, a life science venture capital firm based in Westlake Village, California, focused on incubating and investing in early-stage biotechnology companies to develop life-saving medicines.[[1]](https://mtec-sc.org/investors/westlake-village-biopartners)[[2]](https://westlakebio.com)[[3]](https://westlakebio.com/westlake-village-biopartners-launches-450-million-fund-and-appoints-next-generation-of-leaders/)[[4]](https://www.sec.gov/Archives/edgar/data/1994702/000110465924024091/0001104659-24-024091-index.htm) Established as part of Westlake BioPartners' ecosystem, the fund supports entrepreneurs with hands-on guidance from ideation through clinical and commercial stages, leveraging the firm's deep ties to the Los Angeles biotech community.[[1]](https://mtec-sc.org/investors/westlake-village-biopartners)[[2]](https://westlakebio.com) Westlake BioPartners, founded in September 2018, has raised over $1.3 billion across its funds, including a $450 million third fund launched in July 2023, and has created more than 20 companies, such as Capsida Biotherapeutics, Latigo Biotherapeutics, and ACELYRIN, INC.[[1]](https://mtec-sc.org/investors/westlake-village-biopartners)[[3]](https://westlakebio.com/westlake-village-biopartners-launches-450-million-fund-and-appoints-next-generation-of-leaders/) The firm is led by managing directors Beth Seidenberg, M.D., Mira Chaurushiya, Ph.D., and David Allison, Ph.D., who bring extensive expertise in biotech investing and company-building.[[3]](https://westlakebio.com/westlake-village-biopartners-launches-450-million-fund-and-appoints-next-generation-of-leaders/) As a corporate insider, Westlake Biopartners Opportunity Fund I, L.P. (CIK: 0001811946) recently engaged in trading activity at Kyverna Therapeutics, Inc. (KYTX), holding approximately 10% stake.[[4]](https://www.sec.gov/Archives/edgar/data/1994702/000110465924024091/0001104659-24-024091-index.htm)[[5]](https://www.stockadora.com/insider-trading/insider/0001811946/)

View full insider profile →

Trade Price

$7.50

Quantity

133,333

Total Value

$999,998.00

Shares Owned

4,657,257

Trade Date

Thursday, December 18, 2025

66 days ago

SEC Filing Date

Monday, December 22, 2025

Filed 4 days after trade

HEALTHCAREBIOTECHNOLOGY

About Kyverna Therapeutics, Inc.

Company Overview

No company information available
View news mentioning KYTX

💬 Want Deeper Insight?

Use our AI assistant to ask questions about this trade, the insider, or the company.

Chat with AI

Share this trade

https://insidersignal.ai/trade/2445975

🚀 Track Insider Trades in Real-Time

Create a free account to access our full database of insider trades, AI-powered analysis, price alerts, and discover what corporate executives are buying and selling.

✓ Free forever plan available  •  ✓ No credit card required  •  ✓ Cancel anytime